Refractory Acute Lymphoblastic Leukemia

Also known as: Refractory Acute lymphoblastic leukemia / Acute lymphocytic leukemia refractory / Acute lymphocytic leukaemia refractory / Refractory Acute lymphoblastic leukaemia

DrugDrug NameDrug Description
DB00631ClofarabineClofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed in the U.S. and Canada as Clolar. In Europe and Australia/New Zealand the product is marketed under the name Evoltra. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other types of treatment have failed. It is not known if the drug extends life expectancy. Some investigations of effectiveness in cases of acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) have been carried out.
DB00619ImatinibImatinib is a small molecule kinase inhibitor used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells.
DB01280NelarabineNelarabine is a chemotherapy drug used in T-cell acute lymphoblastic leukemia. Nelarabine is a purine nucleoside analog converted to its corresponding arabinosylguanine nucleotide triphosphate (araGTP), resulting in inhibition of DNA synthesis and cytotoxicity.
DrugDrug NameTargetType
DB00631ClofarabineDNA polymerase alpha catalytic subunittarget
DB00631ClofarabineRibonucleoside-diphosphate reductase large subunittarget
DB00631ClofarabineDeoxycytidine kinaseenzyme
DB00631ClofarabineATP-binding cassette sub-family G member 2transporter
DB00619ImatinibPlatelet-derived growth factor receptor betatarget
DB00619ImatinibTyrosine-protein kinase ABL1target
DB00619ImatinibMast/stem cell growth factor receptor Kittarget
DB00619ImatinibRET proto-oncogenetarget
DB00619ImatinibHigh affinity nerve growth factor receptortarget
DB00619ImatinibMacrophage colony-stimulating factor 1 receptortarget
DB00619ImatinibPlatelet-derived growth factor receptor alphatarget
DB00619ImatinibEpithelial discoidin domain-containing receptor 1target
DB00619ImatinibCytochrome P450 3A4enzyme
DB00619ImatinibBCR/ABL fusion protein isoform X9target
DB00619ImatinibCytochrome P450 1A2enzyme
DB00619ImatinibCytochrome P450 2D6enzyme
DB00619ImatinibCytochrome P450 2C9enzyme
DB00619ImatinibCytochrome P450 2C19enzyme
DB00619ImatinibCytochrome P450 3A5enzyme
DB00619ImatinibCytochrome P450 3A7enzyme
DB00619ImatinibSolute carrier family 22 member 1transporter
DB00619ImatinibMultidrug resistance protein 1transporter
DB00619ImatinibSolute carrier family 22 member 2transporter
DB00619ImatinibATP-binding cassette sub-family G member 2transporter
DB00619ImatinibATP-binding cassette sub-family A member 3transporter
DB00619ImatinibProstaglandin G/H synthase 1enzyme
DB00619ImatinibSerum albumincarrier
DB00619ImatinibAlpha-1-acid glycoprotein 1carrier
DB01280NelarabineAdenosine deaminaseenzyme
DB01280NelarabineDeoxycytidine kinaseenzyme
DB01280NelarabineDeoxyguanosine kinase, mitochondrialenzyme
DB01280NelarabineDNA polymerase alpha catalytic subunittarget
DrugDrug NamePhaseStatusCount
DB00987Cytarabine1Not Yet Recruiting1
DB00541Vincristine1Not Yet Recruiting1
DB09052Blinatumomab1 / 2Not Yet Recruiting1
DB09037Pembrolizumab1 / 2Not Yet Recruiting1
DB11581Venetoclax1 / 2Recruiting1
DB00541Vincristine1 / 2Recruiting1
DB00688Mycophenolate mofetil2Recruiting1
DB00877SirolimusNot AvailableTerminated1